Publication Date: 09 Apr 2013
Citation: Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 2013:7 7-15
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide and is projected to be the third by 2020. COPD is characterized by chronic airflow limitation caused by airway inflammation and parenchymal destruction that is usually progressive. Inhaled bronchodilators continue to be the mainstay of the current management of COPD. Safety and efficacy data of the recently approved medications including aclidinium, glycopyrronium, roflumilast, and indacaterol are reviewed here.
PDF (538.25 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
The staff of Libertas Academica have been exceptionally easy to work with. They continually keep authors updated and are responsive to all requests. They were also very flexible to work with when I had some challenges from my end as an author. Article reviews were received very promptly and were constructive and helpful for improving the manuscript. The online submission system was easy to use and provided clear guidance on what was needed. I highly ...